Comparison of voriconazole concentration in the aqueous humor and vitreous between non-scraped and scraped corneal epithelium groups after topical 1% voriconazole application

Current Eye Research

Volumn 35, Issue 7, 2010, Pages 573-579

  Wei, Li Chen ^a,d   Tsai, Tsun Chung ^b   Tsai, Hin Yeung ^a,c   Wang, Chun Yuan ^a,c   Shen, Ying Cheng ^a,d  

^a TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b TUNGHAI UNIVERSITY   (Taiwan)

^c HUNGKUANG UNIVERSITY   (Taiwan)

^d OVERSEAS CHINESE UNIVERSITY   (Taiwan)

Author keywords

Aqueous humor; Endophthalmitis; Pharmacokinetics; RabbitVoriconazole

Indexed keywords

VORICONAZOLE; ANTIFUNGAL AGENT; EYE DROPS; PYRIMIDINE DERIVATIVE; TRIAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; AQUEOUS HUMOR; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORNEA EPITHELIUM; DEBRIDEMENT; DRUG ABSORPTION; DRUG PENETRATION; DRUG TISSUE LEVEL; EXPERIMENTAL RABBIT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LOADING DRUG DOSE; MAINTENANCE DRUG DOSE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; VITREOUS BODY; ANIMAL; BIOAVAILABILITY; METABOLISM; MICROBIAL SENSITIVITY TEST; RABBIT; SURGERY; TOPICAL DRUG ADMINISTRATION; TRANSPORT AT THE CELLULAR LEVEL;

ADMINISTRATION, TOPICAL; ANIMALS; ANTIFUNGAL AGENTS; AQUEOUS HUMOR; BIOLOGICAL AVAILABILITY; BIOLOGICAL TRANSPORT; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DEBRIDEMENT; EPITHELIUM, CORNEAL; MICROBIAL SENSITIVITY TESTS; OPHTHALMIC SOLUTIONS; PYRIMIDINES; RABBITS; TRIAZOLES; VITREOUS BODY; VORICONAZOLE;

EID: 77954415816     PISSN: 02713683     EISSN: 14602202     Source Type: Journal    
DOI: 10.3109/02713681003760135     Document Type: Article

References (34)

1. Wykoff CC, Flynn HW, Miller D, et al. Exogenous fungal endophthalmitis: Microbiology and clinical outcomes. Ophthalmology. 2008;115:1501-1507.
2. Pfugfelder SC, Flynn HW, Zwickey TA. Exogenous fungal endophthalmitis. Ophthalmology. 1988;95:19-30.
3. Dursun D, Fernandez V, Miller D, et al. Advanced Fusar-ium keratitis progressing to endophthalmitis. Cornea. 2003;22:300-303. (Pubitemid 36578525)
4. Rosenberg KD, Flynn HW, Alfonso EC, et al. Fusarium endophthalmitis following keratitis associated with contact lenses. Ophthalmic Surg Lasers Imaging. 2006;37:310-313. (Pubitemid 44166244)
5. Upadhyay MP, Karmacharya PC, Koirala S. Epidemio-logic characteristics, predisposing factors, and etiologic diagnosis of corneal ulceration in Nepal. Am J Ophthalmol. 1991;111:92-99.
6. Sharma S, Srinivasan M, George C. The current status of Fusarium species in mycotic keratitis in south India. Indian J Med Microbiol. 1993;11:140-147.
7. Rosa RH, Miller D, Alfonso EC. The changing spectrum of fungal keratitis in South Florida. Ophthalmology. 1994;101:1005-1013. (Pubitemid 24183155)
8. Gallis HA, Drew RH, Pickard WW. Amphoterecin B: 30 years of clinical experience. Rev Infect Dis. 1990;12:308-329.
9. Sabo JA, Abdel-Rahman SM. Voriconazole: A new triazole antifungal. Ann Pharmacother. 2000;34:1032-1043.
10. Hariprasad SM, Mieler WF, Holz ER, et al. Determination of vitreous, aqueous, and plasma concentration of orally administered voriconazole in humans. Arch Ophthalmol. 2004;122:42-47. (Pubitemid 38063603)
11. Perfect JR, Marr KA, Walsh TJ. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis. 2003;36:1122-1131.
12. Abel R, Boyle GL. Dissecting ocular tissue for intraocular drug studies. Invest Ophthalmol. 1976;15:216-219.
13. Prajna NV, John RK, Nirmalan PK. A randomised clinical trial comparing 2% econazole and 5% natamycin for the treatment of fungal keratitis. Br J Ophthlamol. 2003;87:1235-1237.
14. Yilmaz S, True M, Maden A. Effcacy of intracameral ampho-tericin B injection in the management of refractory kerato-mycosis and endophthalmitis. Cornea. 2007;26:398-402. (Pubitemid 46684377)
15. Pfaller MA, Messer SA, Hollis RJ. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other flamentous fungi: Report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob Agents Chemother. 2002;46:1032-1037.
16. Marangon FB, Miller D, Giaconi JA. In vitro investigation of voriconazole susceptibility for keratits and endopphthapmi-tis fungal pathogens. Am J Ophthalmol. 2004;137:820-825. (Pubitemid 38582033)
17. Shen YC, Wang MY, Wang CY, et al. Clearance of intra-vitreal voriconazole. Invest Ophthalmol Vis Sci. 2007;48: 2238-2241.
18. Vorwerk CK, Streit F, Binder L, et al. Aqueous humor concentration of voriconazole after topical administration in rabbits. Graefes Arch Clin Exp Ophthalmol. 2008;246:1179-1183.
19. Zhou L, Glickman RD, Chen N, et al. Determination of voriconazole in aqueous humor by liquid chromatography-electrospray ionization-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2002;776:213-220. (Pubitemid 34879070)
20. Shen YC, Wang MY, Wang CY, et al. Pharmacokinetics of intracameral voriconazole injection. Antimicrob Agents Chemother. 2009;53:2156-2157.
21. Sun MX, Chen JQ, Yao MC, et al. Ocular penetration and pharmacokinetics of topical voriconazole in rabbit eyes. Zhonghua Yan Ke Za Zhi. 2008;44:349-353.
22. Vemulakonda GA, Hariprasad SM, Mieler WF, et al. Aqueous and vitreous concentrations following topical administration of 1% voriconazole in humans. Arch Ophthalmol. 2008;126:18-22.
23. Behrens-Baumann W. Mycosis of the Eye and its Adnexa. Basle: Karger, 1999; pp. 171-174.
24. Liou SW, Chiu CJ, Wang IJ. Effect of intracameral injection of lidocaine and carbachol on the rabbit corneal endothelium. J Cataract Refract Surg. 2004;30:1351-1355.
25. Sponsel W, Chen N, Dang D, et al. Topical voriconazole as a novel treatment for fungal keratitis. Antimicrob Agents Chemother. 2006;50:262-268. (Pubitemid 43042931)
26. Arikan S, Lozano-Chiu M, Paetznick V, et al. Microdilu-tion susceptibility testing of amphotericin B, itraconazole, and voriconazole against clinical isolates of Aspergillus and Fusarium species. J Clin Microbiol. 1999;37:3946-3951.
27. Marco F, Pfaller MA, Messer SA, et al. Antifungal activity of a new triazole, voriconazole (UK-109, 496), compared with three other antifungal agents tested against clinical isolates of flamentous fungi. Med Mycol. 1998;36: 433-436. (Pubitemid 28563058)
28. Denning DW, Hanson LH, Perlman AM, et al. In vitro susceptibility and synergy studies of Aspergillus species to conventional and new agents. Diagn Microbiol Infect Dis. 1992;15:21-34.
29. Klepser ME, Malone D, Lewis RE, et al. Evaluation of voriconazole pharmacodynamics using time-kill methodology. Antimicrob Agents Chemother. 2000;44:1917-1920. (Pubitemid 30422948)
30. Peters AM. Fundamentals of tracer kinetics for radiologists. Br J Radiol. 1998;71:1116-1129.
31. Klyce SD, Crosson CE. Transport processes across the rabbit corneal epithelium: A review. Curr Eye Res. 1985;4:323-331.
32. Sasaki H, Yamamura K, Tei C, et al. Ocular permeability of FITC-dextran with absorption promoter for ocular delivery of peptide drug. J Drug Target. 1995;3:129-135.
33. Silling G. Fluconazole: Optimized antifungal therapy based on pharmacokinetics. Mycoses. 2002;45(Suppl 3):39-41.
34. Chang SW, Chou SF, Chuang JL. Mechanical corneal epithelium scraping and ethanol treatment up-regulate cytokine gene expression differently in rabbit cornea. J Refract Surg. 2008;24:150-159.